Genmab A/S (NASDAQ:GMAB) Sets New 1-Year Low - Should You Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $20.47 and last traded at $20.47, with a volume of 10444 shares changing hands. The stock had previously closed at $20.67.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. BMO Capital Markets restated an "outperform" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Redburn Atlantic began coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. Truist Financial reduced their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Trading Down 0.8 %

The company has a market cap of $13.57 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 0.64 and a beta of 0.99. The company's 50 day moving average price is $23.67 and its 200 day moving average price is $26.11.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to analysts' expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the prior year, the firm posted $0.47 EPS. Sell-side analysts predict that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GMAB. Allspring Global Investments Holdings LLC purchased a new position in Genmab A/S during the first quarter worth $43,000. Janney Montgomery Scott LLC boosted its stake in shares of Genmab A/S by 43.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company's stock worth $520,000 after purchasing an additional 5,238 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock valued at $28,000 after purchasing an additional 544 shares during the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in shares of Genmab A/S during the 1st quarter worth $255,000. Finally, Pitcairn Co. raised its position in shares of Genmab A/S by 12.8% in the 1st quarter. Pitcairn Co. now owns 17,290 shares of the company's stock worth $517,000 after buying an additional 1,960 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.